Navigation Links
Strategic Agreement Launches Novel Drug Development Model
Date:9/7/2012

SOLANA BEACH, Calif., Sept. 7, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced a strategic development and investment agreement with Houston-based Professional Compounding Centers of America, Inc. (PCCA). The agreement will allow the companies to develop and share drug-formulation technology, with the goal of creating a new generation of treatments for muscle and joint pain, neuropathic pain and other conditions. PCCA also made a $4 million equity investment in Imprimis in a private transaction.

The agreement will give Imprimis exclusive non-PCCA-member access to PCCA's topical technologies and formulation know-how for delivering drugs directly through the skin. The arrangement is intended to identify development opportunities for new topical medications for new therapeutic applications.

Imprimis' lead drug candidate, Impracor™, a topical non-steroidal anti-inflammatory cream, is expected to enter Phase 3 clinical trials early in 2013. When approved for sale, Impracor would be applied to the site of muscle or joint pain, delivering a clinical dose of medication to the affected area without potential side effects such as stomach irritation or liver problems that have been associated with ingestible, non-steroidal, anti-inflammatory drugs.

The company has also developed Accudel™, a patented topical-delivery platform that can serve as a delivery vehicle for other medications.

"This agreement with PCCA will allow us to develop and implement an entirely new model for creating needed drugs for the treatment of a variety of conditions. Under this model, we will look for ways to repurpose or reformulate existing FDA-approved generic drugs, which would be delivered through our proprietary technologies," said Mark L. Baum, CEO of Imprimis. "We are very excited to enter a strategic relationship with such a well-respected company as PCCA, the largest pharmaceutical compounding organization in the North America."

PCCA provides a variety of products and services to its member compounding pharmacies, which work directly with prescribers to provide patients with specialized medications that are not available in either over-the-counter or prescription form. For the past 30 years, PCCA has been focused on supporting independent pharmacies by delivering a complete portfolio of compounding products, services, education and intellectual property.

PCCA has led in the research, development and study of topical and transdermal technology including its Lipoderm® family of topical bases —the industry's only bases proven to deliver four drugs simultaneously. 

Jim Smith, president of PCCA added: "Through this agreement, we will leverage our knowledge and products to bring new drugs to the market and ultimately heighten awareness and acceptance of topical drug delivery. By building bridges between compounding pharmacists and drug manufacturers, our members will be best positioned to strengthen the role of independent pharmacies in their communities while continuing to play their crucial role in personalized medicine. We are convinced this new model for the development of drugs is an important advancement for the pharmaceutical industry."

Imprimis drug-development strategy calls for repurposing or reformatting existing FDA-approved generic drugs to create new high-value FDA-approved manufactured drugs that address new therapeutic applications. In other words, generic drugs would be combined with Imprimis' patented delivery-technology to create entirely new medications for specific markets that are lacking these medicines.

"Once a potential new drug application has been identified, prior to making an investment, we hope to be able to identify the correct formulation and dosing to protect our investment in new patent applications," said Baum. "We plan to implement a clinical development and a thoughtful regulatory strategy prior to seeking partnerships to bring these market-tested proprietary compounded drug formulations to market. We believe this agreement is a win not only for our two companies, but for the pharmaceutical industry and the patients that it serves."

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Its innovative, patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, its lead pain-product candidate, uses the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues, where the drug exerts its localized anti-inflammatory and analgesic effects. It intends to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. The Imprimis Pharmaceuticals, Inc. website is currently under construction and is expected to launch in September 2012.

About Professional Compounding Centers of America, Inc. (PCCA)

PCCA is the independent compounding pharmacist's complete resource for quality chemicals, equipment, ACPE-accredited training and education, pharmacy software, clinical and business consulting. Its membership includes more than 3,900 independent community-pharmacists in the United States, Canada, Australia and other countries around the world. PCCA's mission is to strengthen the role, position and skills of member compounding pharmacists so they can meet the unique healthcare needs of patients through exceptional service, high-quality products, shared innovations and education.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact: Mark L. Baum
Imprimis Pharmaceuticals, Inc.
(858) 433-2800


'/>"/>
SOURCE Imprimis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
3. Herborium Announces Continuing Progress In Key Strategic Initiatives
4. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
5. UBM Canon, the Global MedTech Authority, Announces Strategic Alliance with ITG Market Research, a Preeminent Industry Research Organization
6. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
7. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
8. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
11. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Click here ... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... a definitive agreement to acquire Valley Campus Pharmacy, ... ("TNH"), a leading specialty pharmacy that provides individualized ... California . In 2015, TNH generated approximately ...
(Date:4/28/2016)... 28, 2016  The blood testing market in ... to Kalorama Information and The Freedonia Group in a ... acid testing.  The healthcare research firm said that ... blood collection stations and in improving testing at the ... report, Blood Testing Market in China ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 02, 2016 , ... According to an American Psychological Association article, ... abused before the age of 18. Of those who survive, many still face effects ... , In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories ...
(Date:5/2/2016)... PARSIPPANY, N.J. (PRWEB) , ... May 02, 2016 ... ... - Healthcare Research & Analytics EVP and GM Jim Callandrillo and Duane ... during the 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- which ... announced today the outcome of their partnership with Yoloha Yoga- producers of high quality ... Board.” , SUP yoga has seen a dramatic rise in popularity throughout the last ...
(Date:5/2/2016)... ... , ... Marshall Votta, Josh Holmes and Laura Sandman have joined RowdMap, Inc. ... Inc.’s market growth across both health plans and provider organizations who use government benchmark ... based care. , Marshall Votta joins RowdMap, Inc. as Chief Market Officer and takes ...
(Date:5/1/2016)... ... ... 2 is a set of versatile and smooth logo reveals built exclusively for Final ... a unique logo reveal in just a matter of minutes. Custom settings give the user ... add a uniquely animated logo to any photos or videos. , ProBrand Reveal comes packaged ...
Breaking Medicine News(10 mins):